120 likes | 139 Views
According to the latest research report by IMARC Group, The global migraine drugs market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2023-2028.<br><br>More Info:- https://www.imarcgroup.com/migraine-drugs-market
E N D
Global Migraine Drugs Market Research and Forecast Report 2023-2028 Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2019 IMARC All Rights Reserved
Report DescriptionAbout IMARC Group The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Report Description Global Migraine Drugs Market Research Report: The latest report by IMARC, titled “Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” the global migraine drugs market is expected to grow at a CAGR of 4.5% during 2023-2028. Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light, sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce the frequency of migraines. Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample
Report Description and Highlights Report Description Global Migraine Drugs Market Trends: According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people getting affected by the condition worldwide. This represents the primary factor that has increased the demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic targets, which are in different development stages. Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
Report Description and Highlights Report Description Market Summary: Breakup by Treatment Type: • Abortive Treatment • Preventive Treatment Breakup by Drug Type: • Triptans • Ergot Alkaloids • NSAIDs • Acetylcholine Inhibitors/ Neurotoxins • Ditans • CGRP mAbs • Others Breakup by Route of Administration: • Oral • Injectable • Others
Report Description and Highlights Report Description Breakup by Distribution Channel: • Hospital-Based Pharmacies • Retail Pharmacies • Others Breakup by Region: • North America • United States • Canada • Asia Pacific • China • Japan • India • South Korea • Australia • Indonesia • Others • Europe • Germany • France
Report Description and Highlights Report Description • United Kingdom • Italy • Spain • Russia • Others • Latin America • Brazil • Mexico • Others • Middle East and Africa
Report Description and Highlights Report Description Competitive Landscape with Key Players: • • • • • • • • • • • • • • Abbott Laboratories Allergan Plc (Abbvie Inc.) Amgen Inc. AstraZeneca Plc Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals) Eisai Co. Ltd. Eli Lilly and Company Endo International Plc GlaxoSmithKline Plc Johnson & Johnson Merck & Co. Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Limited View Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market
We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients
We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients
Report Description and Highlights Report Description © 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com